Table 1.

Characteristics of the 6 patients who developed stroke during the posttrial follow-up


Pt no.

Age, y

Sex

Trial SC/TX

Posttrial TX/no TX

Time from study entry to stroke, mo

Maximum baseline TCD,*cm/s

Last TCD before stroke, cm/s

Baseline MRI

Posttrial MRI

Posttrial MRA

Status after discharge
1   9   F   SC   No TX   23   248   343; 1 mo BS   Positive   Worse   Normal   No symptoms  
2   8   M   SC   No TX   28   221   202; 1 mo BS   Negative   Negative   Not done   Unknown  
3   7   M   SC   No TX   31   252   202; 2 mo BS   Positive   Worse   Normal   Mild-moderate physical disability  
4   10   F   TX   Stopped TX   42   220   158 on TX; 221 8 mo BS   Positive   Worse   Normal   Symptoms but no physical disability  
5   10   F   SC   TX   42   293   254 27 mo BS; inadequate 11 mo BS   Positive   Worse   Worse   Symptoms but no physical disability  
6
 
11
 
M
 
SC
 
TX
 
43
 
304
 
222 14 mo BS; inadequate 9 mo BS
 
Positive
 
Worse
 
Worse
 
Symptoms but no physical disability
 

Pt no.

Age, y

Sex

Trial SC/TX

Posttrial TX/no TX

Time from study entry to stroke, mo

Maximum baseline TCD,*cm/s

Last TCD before stroke, cm/s

Baseline MRI

Posttrial MRI

Posttrial MRA

Status after discharge
1   9   F   SC   No TX   23   248   343; 1 mo BS   Positive   Worse   Normal   No symptoms  
2   8   M   SC   No TX   28   221   202; 1 mo BS   Negative   Negative   Not done   Unknown  
3   7   M   SC   No TX   31   252   202; 2 mo BS   Positive   Worse   Normal   Mild-moderate physical disability  
4   10   F   TX   Stopped TX   42   220   158 on TX; 221 8 mo BS   Positive   Worse   Normal   Symptoms but no physical disability  
5   10   F   SC   TX   42   293   254 27 mo BS; inadequate 11 mo BS   Positive   Worse   Worse   Symptoms but no physical disability  
6
 
11
 
M
 
SC
 
TX
 
43
 
304
 
222 14 mo BS; inadequate 9 mo BS
 
Positive
 
Worse
 
Worse
 
Symptoms but no physical disability
 

BS indicates before stroke.

*

Values represent the highest time-averaged mean velocity in the middle cerebral or internal carotid artery during the confirmatory TCD before randomization.